| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 10.5MM | +27% |
| Gross Profit | 3.5MM | - |
| Cost Of Revenue | 7MM | +41% |
| Operating Income | -3MM | +45% |
| Operating Expenses | 6.5MM | - |
| Net Income | -3.9MM | -253% |
| R&D | 1.5MM | -4% |
| G&A | 6.4MM | +25% |
| Amortization | 273K | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
ORLANDO, Fla., April 01, 2024--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,425 shares of the Company’s common stock. The options were granted as of April 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listin
There's been a notable change in appetite for LENSAR, Inc. ( NASDAQ:LNSR ) shares in the week since its yearly report...
LENSAR ( NASDAQ:LNSR ) Full Year 2023 Results Key Financial Results Revenue: US$42.2m (up 19% from FY 2022). Net loss...
ORLANDO, Fla., March 04, 2024--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2023 and provided an update on key operational initiatives.
ORLANDO, Fla., February 26, 2024--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2023 financial results will be released before market open on Monday, March 4, 2024. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Monday, March 4, 2024 to discuss the financial results and recent c
Insiders who bought LENSAR, Inc. ( NASDAQ:LNSR ) in the last 12 months may probably not pay attention to the stock's...
LENSAR, Inc. (NASDAQ:LNSR) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Good morning, and thank you for your participation. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to Cameron Radinovic of Burns McClellan, Mr. Radinovic, please go ahead. Cameron Radinovic : Thank […]
ORLANDO, Fla., November 09, 2023--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2023 and provided an update on key operational initiatives.
ORLANDO, Fla., November 02, 2023--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s third quarter 2023 financial results will be released before market open on Thursday, November 9, 2023. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, November 9, 2023 to discuss the financial results and recent corpor